Liraglutide STADA (liraglutide)

Where it stands

Liraglutide STADA (liraglutide) is authorised in the EU. The European Commission decision of 15 July 2026 granted the marketing authorisation to STADA Arzneimittel AG. The CHMP had adopted a positive opinion on 21 May 2026.

The authorised indication is treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise. The therapeutic area is diabetes mellitus.

The interval between CHMP opinion and EC decision was about 55 days. That is consistent with the usual EU process, in which the Commission converts a CHMP opinion into a legally binding decision. The records show no other milestones, such as clarification steps or a withdrawal.

Regulatory pathway and designations

The records show a two-step EU centralised sequence: a CHMP positive opinion followed by an EC approval decision. They do not state the legal basis of the application (for example generic, hybrid or full application). They also do not say which medicine, if any, is the reference product, or whether any data package was submitted. Those points should be checked in the EPAR and product information once available.

The only designation recorded is additional monitoring. No orphan, PRIME, conditional approval or exceptional-circumstances status is listed.

The same substance is also authorised in the EU under other names: Ablymico, Victoza, Saxenda and Xultophy. The records give no detail on their indications, their holders or their relationship to Liraglutide STADA. Any comparison of scope or positioning would need additional sources.

Safety and pharmacovigilance

The records contain no safety data for this product. They include no adverse-event information, risk management plan content, contraindications or post-authorisation commitments, so no product-specific safety conclusions can be drawn here.

The additional monitoring designation means the product is subject to intensified safety surveillance. In the EU such products carry a black inverted triangle in the product information, with a standard statement encouraging healthcare professionals and patients to report suspected adverse reactions. The designation is a pharmacovigilance transparency measure. It does not by itself indicate a specific safety problem.

The indication includes children aged 10 and above. Paediatric use is therefore part of the authorised scope, and the full product information and risk management plan should be reviewed for how it is addressed. The records do not describe this.

What to watch

The records give no launch timing, country availability, pricing or reimbursement information, so none is assumed here. Useful next steps are to review the published EPAR and the product information, confirm the legal basis and reference product, and check the risk management plan and any additional risk minimisation measures.

Additional monitoring status is normally reviewed over time. Whether and when it is removed is not stated in the records.

For competitive or portfolio assessment, the existing liraglutide products listed (Ablymico, Victoza, Saxenda, Xultophy) should be compared using their own authorisation details. The records do not supply those details.